FDA Approves First Treatment for Rare MCT8 Deficiency

The FDA has granted approval to tiratricol (Emcitate) as the inaugural treatment for peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency, also known as Allan-Herndon-Dudley syndrome. This approval marks a significant milestone for individuals with this rare genetic disorder, providing a therapy to reduce excess circulating thyroid hormone and alleviate strain on the heart and metabolism.